Vol. 5 No. 7 (2025)
Reimbursement Recommendations

Leuprolide Mesylate (Camcevi)

decorative image of the issue cover

Published July 22, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Camcevi should be reimbursed by public drug plans for the treatment of adult patients with advanced prostate cancer if certain conditions are met.
  • Camcevi should only be covered to treat adult patients with prostate cancer according to the reimbursement criteria used by public drug plans for androgen deprivation therapies (ADTs) for the treatment of prostate cancer.
  • The cost of Camcevi should not exceed the drug program cost of treatment with the least costly alternative treatment.